Business
Jaguar Health Reports 2023 Financial Results
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18%Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 millionTop line results expected forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaREMINDER: Jaguar to host investor webcast Monday, April 1st at 8:30 a.m. Eastern regarding Q4 2023 financials and company updates; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / April 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today reported consolidated financial results for the year ended December 31, 2023.The combined net revenue for Mytesi® and the Company's other crofelemer prescription product, Canalevia®-CA1, was approximately $9.7 million in the year 2023, representing a decrease of 18% over the combined net revenue in the year 2022, which totaled approximately $11.9 million. The combined net revenue for Mytesi and Canalevia-CA1 was approximately $2.3 million in the fourth quarter of 2023, representing a decrease of 18% over prescription product net revenue in the third quarter of 2023, which totaled approximately $2.8 million, and a decrease of approximately 30% over prescription product net revenue in the fourth quarter of 2022, which totaled approximately $3.3 million.Lisa Conte, Jaguar's president and CEO, said, \"Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency. Top line results from this pivotal study are forthcoming.\"Jaguar is supporting investigator-initiated and IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected in 2024. In accordance with the guidelines of spec...